Valaris
VAL · NYSE
About VAL
- Employees
- 5,070
- Headquarters
- Hamilton
- Listed
- May 3, 2021
- Sector
- Energy
- Industry
- Energy Equipment & Services
- Website
- valaris.com
VAL key statistics
- Market cap
- 5.92B
- Price-earnings ratio
- 6.74
- Dividend yield
- —
- Average volume
- 995.87K
- Volume
- 888.67K
- Open price
- $90.08
- High today
- $91.50
- Low today
- $87.20
- 52 Week high
- $114.12
- 52 Week low
- $48.09
Valaris (VAL) at a glance
Valaris (VAL) last traded at $88.35, with a market cap of 5.92B and a price-to-earnings ratio of 6.74.
Today the stock has traded between $87.20 and $91.50. The current price is 1.3% above the day's low and 3.4% below its high.
Volume so far is 888.67K shares, in line with the average of 995.87K shares a day.
Over the past year Valaris has ranged from $48.09 to $114.12, and now sits 61% of the way up that range.
Valaris met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported $0.72 per share against an estimate of $0.419.
The average analyst price target is $82.28, 6.9% below the current price, from 4 recent ratings.
Analyst ratings
Latest rating from each analyst over the past 12 months
- Buy0.0%
- Hold100.0%
- Sell0.0%
- Low
- $50.50
- Now
- $88.35
- High
- $109.20
VAL earnings
Earnings per share, reported against the analyst estimate
Beat the estimate in 6 of the last 8 quarters, by 313.5% on average.
- Q3 FY24: reported $0.88 per share against an estimate of $1.05
- Q4 FY24: reported $1.88 per share against an estimate of $1.04
- Q1 FY25: reported $1.93 per share against an estimate of $1.24
- Q2 FY25: reported $1.61 per share against an estimate of $1.27
- Q3 FY25: reported $2.65 per share against an estimate of $1.17
- Q4 FY25: reported $10.26 per share against an estimate of $0.6336
- Q1 FY26: reported -$0.24 per share against an estimate of -$0.1229
- Q2 FY26: reported $0.72 per share against an estimate of $0.419
VAL news
- Press releaseBusiness Wire
- Press releaseBusiness Wire
Valaris Announces Contract Awards and Fleet Status Updates
- Press releasePRNewswire
Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?
- Press releasePRNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Proxy and Looming Shareholder Merger Vote --VRME, VAL, LAB and FTHM
- Press releasePRNewswire
INVESTOR ALERT: The M&A Class Action Firm Launches Investigation of the Merger--IRDM, VRME, VAL and LAB
- Press releaseBusiness Wire
Valaris Issues Fleet Status Report
- Press releaseBusiness Wire
Valaris Reports Second Quarter 2026 Results
- Press releaseBusiness Wire
Valaris Schedules Second Quarter 2026 Earnings Release
Similar companies
Companies in the same industry as Valaris
Most active stocks
Highest trading volume today
- EARIEntertainment Arts Research$0.0003−16.67%
- SEIISharing Economy International$0.0004+100.00%
- NWGLCL Workshop Group$0.1522+27.90%
- TMSHTrans Global Assets$0.0002+0.00%
- AEFIAmerican EcoFuels$0.0007+0.00%
- CBDW1606$0.0002+0.00%
- FITYFifty 1 Labs$0.0001−66.67%
- PRSOPeraso$0.5914+54.13%
- SDSTStardust Power$0.02−23.66%
- SHFSSHF Holdings$0.0899−4.36%
- FRTTFort Technology$0.7121+32.63%
- CBDLCBD Life Sciences$0.0002−25.00%
Newly listed
Companies that went public in the past six weeks
- TCXBTCGX Acquisition Corp. II$10.56+1.54%
- CTYCITY THERAPEUTICS$20.83−2.94%
- IAMIambic Therapeutics$16.01−2.02%
- AMROAmaero$5.68+1.25%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.28−0.10%
- TRXBTRex Bio$14.44−2.43%
- RTSNRetension Pharmaceuticals$16.18−0.92%
- PAXGUPine Tree Acquisition$9.98+0.00%
- PORTUSouthport Acquisition Corp. IIListed Oct 1, 2026
- CHWMChilwa Minerals$5.18+3.39%
- ACCVAccelevation Holdings$12.31−1.44%
- RZAIROZE AI$10.28+1.28%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.